| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.5 | 3e-42 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.48 | 2e-40 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.45 | 7e-36 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.38 | 7e-35 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.42 | 8e-34 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.41 | 1e-31 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.39 | 3e-31 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.41 | 1e-30 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.4 | 4e-29 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.39 | 7e-29 |